

ASX ANNOUNCEMENT

28 JULY 2015



COGSTATE SIGNS US\$1.2M SALES CONTRACT

BRINGING TOTAL CONTRACTS SIGNED IN JULY TO US\$2.3M

SUMMARY

- Cogstate technology selected for use in Phase II clinical trial studying Alzheimer's disease
- Contract value is US\$1.2 million, bringing the total value of contracts signed since 1 July 2015 to US\$2.3 million
- Existing sales contracts will generate A\$13.0 million of clinical trials revenue in FY16

Cogstate (ASX.CGS) has today announced that it has signed a contract for its computerised tests of cognition to be used in a Phase II clinical trial of patients with prodromal and mild dementia due to Alzheimer's disease. The contract value of US\$1.2 million will be recognised over the life of the study.

Today's contract takes the total value of clinical trials sales contracts signed since 1 July 2015 to US\$2.3 million.

Earlier this month, Cogstate provided details of contracted clinical trials revenue that will be recognised in future periods. Below the table has been updated to take account of contracts signed this month:

Contracted Clinical Trials – Revenue¹

	As at 28 July 2015		As at 30 June 2015		As at 30 June 2014	
Year 1	FY16	A\$13.0m	FY16	A\$10.9m	FY15	A\$6.2m
Year 2	FY17	A\$7.0m	FY17	A\$6.5m	FY16	A\$3.1m
Years 3 – 5	FY18 – FY20	A\$4.5m	FY18 – FY20	A\$4.0m	FY17 – FY20	A\$1.3m
Total		A\$24.5m		A\$21.4m		A\$10.7m

1. Contracts are denominated in US\$. Spot rate at 30 June has been used to calculate the A\$ equivalent. The rate used at 30 June 2015 and 28 July 2015 was 0.765. The rate used at 30 June 2014 was 0.9

ABOUT COGSTATE

Cogstate Ltd (ASX:CGS) is a leading cognitive science company focused on optimising the measurement of cognition to guide decision-making. Cogstate commercialises rapid, reliable and highly sensitive computerised cognitive tests for clinical trials, academic research and healthcare. In its Clinical Trials business, Cogstate provides both novel technologies and expert professional services for clinical research programs seeking to demonstrate a drug's impact on cognition. Delivering solutions spanning the continuum from study design to final statistical analysis, Cogstate's latest Clinical Trials offering, Precision Recruitment™ is a powerful solution based on an online prescreening portal to accelerate the identification and engagement of qualified candidates for clinical trials in high-need indications such as Alzheimer's disease.

For further information contact:

Brad O'Connor
Cogstate Chief Executive Officer
+613 9664 1300 or 0411 888 347
boconnor@cogstate.com

Kyahn Williamson
Buchan Consulting
0401 018 828
kwilliamson@buchanwe.com.au